Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections
Status:
Completed
Trial end date:
2019-09-07
Target enrollment:
Participant gender:
Summary
This study evaluates the the pharmacokinetics of posaconazole (new solid oral and IV) given
as prophylaxis to patients who are at risk for developing fungal infections after receiving
conditioning therapy (except strictly non-myeloablative (NMA)) for allogeneic Stem Cell
Transplant (SCT), remission induction chemotherapy for acute myeloid leukemia (AML) or myelo
dysplastic syndrome (MDS) or being treated for severe graft versus host disease (GvHD) and
determines the impact of mucositis on the pharmacokinetics of posaconazole new solid oral.